Kura Oncology Balance Sheet Health
Financial Health criteria checks 6/6
Kura Oncology has a total shareholder equity of $466.1M and total debt of $9.4M, which brings its debt-to-equity ratio to 2%. Its total assets and total liabilities are $515.1M and $49.0M respectively.
Key information
2.0%
Debt to equity ratio
US$9.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$491.52m |
| Equity | US$466.07m |
| Total liabilities | US$49.05m |
| Total assets | US$515.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KUR's short term assets ($499.8M) exceed its short term liabilities ($33.5M).
Long Term Liabilities: KUR's short term assets ($499.8M) exceed its long term liabilities ($15.6M).
Debt to Equity History and Analysis
Debt Level: KUR has more cash than its total debt.
Reducing Debt: KUR's debt to equity ratio has reduced from 3% to 2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KUR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KUR has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 19.9% each year.